SLOTPLAYERSTATUSSTARTS THROUGH W5WEEK 7 PTSPOINTS WHILE ROSTERED THROUGH W5
BenchJosh AllenQB • BUF—50.0158.3
WRCeeDee LambWR • DAL—525.4120.3
TEGeorge KittleTE • SF—413.880.3
RBRJ HarveyRB • DEN—218.344.8
BenchKhalil ShakirWR • BUF—20.044.6
FLEXRashid ShaheedWR • SEA—44.641.1
KEddy PineiroK • SF—5-1.037.5
IRTravis Etienne Jr.RB • NO—30.032.9
FLEXTreVeyon HendersonRB • NE—43.632.7
D/STBroncos D/STD/ST • ——17.016.5
RBKendre MillerRB • ——15.610.5
BenchHunter HenryTE • ———13.1—
BenchRachaad WhiteRB • ———0.0—
WRDeMario Douglas • ——4.3—
QBKyler Murray • ——15.4—
BenchTank Dell • ——5.1—
BenchSamaje Perine • ——9.0—
LATEST RESULT
L 97.00–128.80 vs Mr Hopkins Opus
WEEK 5 COVERAGE
CeeDeep fell 141.46–106.75 to Pollard Greens and is 3–2. Josh Allen scored 34.5; CeeDee Lamb supplied 1.9, an inconvenient split for the naming department.
UNAUTHORIZED BIOGRAPHY
Compiled from league records, disputed testimony and messages presented without context.
PERSONNEL 01
Matt McGrath
Chief Naming Compliance Officer
KNOWN AS: Matty McGrath
Matty McGrath entered the league with a functioning team name, Josh Allen and no meaningful alias infrastructure. The organization considers this restraint a competitive advantage. After Allen’s five-touchdown Thursday performance, CeeDeep briefly suspended normal operations and asked the remaining players not to complicate anything.
CURRENT INSTITUTIONAL POSTURE3-4 • 8 in the table • Week 7 complete
INSTITUTIONAL TENDENCIES
01Maintains literal team-name assets
02Relies on Josh Allen escalation
03Operates without alias department
CAREER INCIDENTS
Week 1 — Received 41.26 from Allen and lost.
Week 2 — Allen and Lamb combined for 83.52.
Week 3 — Beat Royrek 121.76–113.84 to move to 2–1.
SEASON / LEADING RETURNS
01Josh Allen — 158.3
02CeeDee Lamb — 120.3
03George Kittle — 80.3
RECENT TRANSACTIONS
2026-09-02Free-agent moveAdded Hunter Henry • $0
FRANCHISE MYTHOLOGY
FILE 01
Naming Compliance
CeeDee and Shaheed remain on premises.
FILE 02
Matty McGrath
currently operating without an alias department.
RECENT COVERAGE
No dedicated coverage yet. This should not be interpreted as institutional approval.
Brief